Literature DB >> 21823054

Stimulation of fat oxidation, but no sustained reduction of hepatic lipids by prolonged pharmacological inhibition of acetyl CoA carboxylase.

M Glien1, G Haschke, K Schroeter, A Pfenninger, G Zoller, S Keil, M Müller, A W Herling, D Schmoll.   

Abstract

Acetyl CoA carboxylase isoforms 1 and 2 (ACC1/2) are key enzymes of fat metabolism and their inhibition has been postulated to be beneficial for the treatment of the metabolic syndrome by decreasing ectopic fat accumulation. In order to validate this approach pharmacologically, we characterized the chronic effect of the small molecule ACC1/2 inhibitor SAR210 in 2 rodent models of fatty liver. Chronic administration of SAR210 increased serum ketone levels in both diet-induced obese mice and female ZDF rats. The inhibitor neither reduced hepatic triglycerides nor influenced body weight in either diet-induced obese mice or female ZDF rats. Thus, chronic pharmacological inhibition of ACC1/2 stimulated fat oxidation, which was, however, not sufficient to reduce hepatic triglycerides. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21823054     DOI: 10.1055/s-0031-1283138

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  5 in total

1.  Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein.

Authors:  Richard G Lee; Wuxia Fu; Mark J Graham; Adam E Mullick; Donna Sipe; Danielle Gattis; Thomas A Bell; Sheri Booten; Rosanne M Crooke
Journal:  J Lipid Res       Date:  2012-12-06       Impact factor: 5.922

Review 2.  Structure and function of biotin-dependent carboxylases.

Authors:  Liang Tong
Journal:  Cell Mol Life Sci       Date:  2012-08-07       Impact factor: 9.261

3.  Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes.

Authors:  David A Griffith; Daniel W Kung; William P Esler; Paul A Amor; Scott W Bagley; Carine Beysen; Santos Carvajal-Gonzalez; Shawn D Doran; Chris Limberakis; Alan M Mathiowetz; Kirk McPherson; David A Price; Eric Ravussin; Gabriele E Sonnenberg; James A Southers; Laurel J Sweet; Scott M Turner; Felix F Vajdos
Journal:  J Med Chem       Date:  2014-12-11       Impact factor: 7.446

4.  Chronic Activation of Hepatic Nrf2 Has No Major Effect on Fatty Acid and Glucose Metabolism in Adult Mice.

Authors:  Sebastian Brachs; Angelika F Winkel; James Polack; Hui Tang; Maria Brachs; Daniel Margerie; Bodo Brunner; Kerstin Jahn-Hofmann; Hartmut Ruetten; Joachim Spranger; Dieter Schmoll
Journal:  PLoS One       Date:  2016-11-04       Impact factor: 3.240

5.  Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice.

Authors:  Sebastian Brachs; Angelika F Winkel; Hui Tang; Andreas L Birkenfeld; Bodo Brunner; Kerstin Jahn-Hofmann; Daniel Margerie; Hartmut Ruetten; Dieter Schmoll; Joachim Spranger
Journal:  Mol Metab       Date:  2016-08-13       Impact factor: 7.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.